Company: OSRH
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001213900-25-109054
Chunk: 10

Company: OSR Holdings, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
 and was expensed
as incurred.

5

Details of shareholders as of September 30, 2025
are as follows:

    Name of Shareholder 
    Number of ordinary share  
    Percentage of ownership 
  
    Bellevue Global Life Sciences Investors LLC 
     1,332,500  
     5.63%
  
    BCM Europe AG 
     8,612,634  
     36.38%
  
    Bellevue Capital Management LLC 
     3,123,970  
     13.20%
  
    Duksung Co.,Ltd. 
     1,420,215  
     6.00%
  
    Others 
     9,181,898  
     38.79%
  
    Total 
     23,671,217  
     100.00%

As of September 30, 2025, there were 23,671,217 shares of the registrant’s
common stock outstanding.

Details of investments in subsidiaries as of September
30, 2025 are as follows:

  Name of subsidiary  Share capital   Percentage of ownership   Principal activities  VAXIMM AG (“VAXIMM”)  $778,208    100.00%  Biotech (drug development)  RMC Co., Ltd. (“RMC”)   24,961    100.00%  Medical device distribution  Darnatein Co., Ltd. (“Darnatein”)   4,611,801    100.00%  Biotech (drug development)  OSR Holdings, Inc. ("OSRI") (*1)   2,450    N/A  SPAC 

Key financial information of the subsidiaries
at September 30, 2025 are as follows :

    Name of subsidiary 
    Asset  
    Liability  
    Equity  
    Sales  
    Net
 Income(loss) 
  
    VAXIMM AG 
    $638,405  
    $275,103  
    $363,302  
    $74,031  
    $(206,841)
  
    RMC Co.,Ltd 
     1,342,303  
     1,123,849  
     218,453  
     2,450,506  
     (490,105)
  
    Darnatein Co.,Ltd